Shares Issued
As at 20 July 2022, the number of shares in issue was 26,014,946. The company does not hold any ordinary shares in treasury.
Significant Shareholders
At 20 July 2022, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company:
| Shareholder | No. of ordinary shares | % of issued share capital |
|---|---|---|
| Invest Northern Ireland | 3,197,865 | 12.29 |
| Amati Global Investors Limited | 2,341,463 | 9.00 |
| Viridian Growth Fund LP | 1,831,500 | 7.04 |
| Octopus Investments Limited | 1,525,258 | 5.86 |
| Hargreave Hale Limited | 1,402,439 | 5.39 |
| Jim Johnston | 1,317,325 | 5.06 |
| Canaccord Genuity | 1,268,865 | 4.88 |
| Livingbridge VC LLP | 1,219,512 | 4.69 |
| Unicorn AIM VCT plc | 1,219,512 | 4.69 |
| Paul Warwick | 1,030,363 | 3.98 |
Director Shareholdings
| Director | No. of ordinary shares | % of issued share capital |
|---|---|---|
| Dr Richard John Buick | 631,250 | 2.43 |
| Dr Simon Gordon Douglas | 255,800 | 0.98 |
| Dr Alan Mawson 1 | 124,000 | 0.48 |
| Sonya Maria Ferguson | 92,567 | 0.36 |
| Dr Adrian Kinkaid | 4,000 | 0.02 |
| Colin James Walsh 2 | - | - |
| James Alexander Fair | - | - |
(1) Alan Mawson is a non-executive director of Clarendon Fund Managers Limited ("Clarendon") and sits on Clarendon's investment committee. Clarendon is the fund manager for Nitech Growth Fund LP which holds 358,850 Ordinary Shares and Viridian Growth
Fund LP which holds 1,831,500 Ordinary Shares.
(2) Colin Walsh is the Chief Executive and founder of Crescent Capital NI Limited, which is the fund manager for Crescent Capital III LP which holds 613,382 Ordinary Shares.
Shares not in public hands
Insofar as it is aware, as at 20 July 2022, 15.12% of the Company's securities is not in public hands.
Statement of the Rights of Shareholders
The rights of shareholders are governed by UK law.
Restrictions in transfer of AIM securities
There are no restrictions on the transfer of the Company's ordinary shares.
UK City Code on Takeovers and Mergers
The Company is subject to the provisions of the City Code on Takeover and Mergers.
Other exchanges and trading platforms
Fusion Antibodies has not applied or agreed to have any of its securities admitted or traded on any other exchanges or trading platforms.
Shareholder Circulars
Page last updated: 7 October 2022
